<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064894</url>
  </required_header>
  <id_info>
    <org_study_id>OUCH</org_study_id>
    <secondary_id>MOP-125943</secondary_id>
    <nct_id>NCT02064894</nct_id>
  </id_info>
  <brief_title>Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries</brief_title>
  <official_title>A Randomized Controlled Trial of Oral Analgesic Utilization for Pain Management of CHildhood Musculoskeletal Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain management for children presenting to the emergency department (ED) with an injured limb
      is often under-treated, even though it is known that broken arms and legs cause moderate to
      severe pain. Further, children are less likely to receive appropriate pain medicine than
      adults with similar injuries. This study aims to improve the pain treatment of children who
      present to the ED with a suspected fracture, or broken bone or severe sprain. The
      investigators will compare the use of 3 different possible medication combinations (ibuprofen
      alone, oral morphine alone, or combined ibuprofen and oral morphine) to determine which
      combination is the best at treating children's pain. The investigators also plan to verify
      the safety of using these different drugs to treat children's pain.

      The investigators strongly believe that children's pain should be optimally treated in the
      ED. Adequately relieving children's pain is crucial, as inadequate pain treatment can have
      both short and longterm effects on the child. It also generates unnecessary stress for both
      the child and their caregivers/parents. Given this knowledge, the investigators feel that
      their study has the potential to impact care provided in EDs, and improve pain management
      safely, for children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale. Musculoskeletal trauma (MSK-T) in children is very common and almost universally
      painful. Standards for children's pain management of MSK-T in the Emergency Department (ED)
      vary greatly between Canadian hospitals and, overall, pain is very poorly treated. This
      inadequate pain treatment can have significant acute and chronic negative effects. Previous
      studies have determined that monotherapy with ibuprofen, the most commonly prescribed oral
      analgesic in the ED, is likely providing inadequate pain management for children. In response
      to this problem, clinicians have turned back to classic oral opioids (eg morphine) and are
      experimenting with combination therapies. To date, few studies have focused on the efficacy
      of a combination of a non-steroidal anti-inflammatory drug (NSAID) (eg ibuprofen) and an
      opioid (eg morphine). Such a combination of analgesics is known to potentiate pain relief by
      blocking it at the level of both the peripheral and the central nervous system. By combining
      two drugs with different mechanisms of action, we may be able to provide additive analgesic
      effects. To our knowledge, no studies have ever studied the efficacy and safety of this
      combination of medication for MSK-T in pediatric EDs. Primary Hypothesis: For children with a
      MSK-T in the ED, the addition of morphine to ibuprofen is safe and provides better pain
      relief than either of the two drugs alone. Primary Research Question: For children with a
      MSK-T in the ED, is a combination of oral morphine (0.2 mg/kg) and oral ibuprofen (10 mg/kg)
      more efficacious than either of the two drugs, alone, in decreasing pain scores to &lt;30 mm, 60
      minutes after administration?

      Methods. Design: This study is a double-blind, placebo-controlled, two center, three-arm,
      randomized clinical trial (RCT). Patients will be randomized to receive either: (a) ibuprofen
      (10mg/kg) + placebo or (b) morphine (0.2 mg/kg) + placebo or (c) morphine (0.2mg/kg) +
      ibuprofen (10mg/kg). Setting: Stollery Children's Hospital (Edmonton, AB) and CHU
      Ste.Justine's pediatric hospital (Montreal, PQ). Inclusion criteria: We will include
      children: (a) between the ages of 8 and 17 years; (b) visiting the ED with an injured upper
      or lower limb that is neither obviously deformed, nor neurovascularly compromised, (c) with a
      self-reported pain score &gt;30 mm on a 0 to100mm Visual Analogue Scale (VAS), where 0 mm
      corresponds to no pain and 100 mm to the worst pain the child has experienced, and (d) who
      understand French or English. Sample Size: Based on previous studies, we expect that between
      25-52% (Clark et al., 2007, Le May et al., 2013) of children will achieve a VAS &lt; 30 mm at 60
      minutes in the ibuprofen arm. We have conservatively set the proportion of children with VAS
      &lt; 30 mm at 60 min to 50%. A sample size of 500 will be then necessary to provide at least 80%
      power to detect a 20% absolute difference in proportion using a two-tailed with an alpha
      level of 5%. In order to ensure an overall alpha level of 5%, a Bonferroni correction has
      been applied in order to take into account the 3 pairwise comparisons that will be performed.
      Primary Outcome and Measurement: The primary outcome measure will be pain intensity score
      under 30 mm at 60-minutes after medication administration, using the VAS). Primary Safety
      Outcomes: We will also assess clinical measures of safety by monitoring oxygen saturation at
      30 minutes intervals, up until 120 minutes. Level of sedation/alertness, as well as the
      respiratory rate, of each child will be monitored at set time points in the study, up until
      120 minutes. Participating children will be followed up (via phone call) at 24 hours, to
      record any latent side effects or adverse events. Further, acceptability of the intervention
      will be assessed.

      Relevance: Our proposed work will be the first RCT to investigate if there is some additive
      effect of a bi-therapy of pain with ibuprofen and morphine. In summary, currently available
      research supports ibuprofen as the monotherapy agent of choice. However, given concerns
      regarding its ability to provide adequate relief on its own, smaller studies looked at
      morphine as a possible alternative combined to ibuprofen. Very few studies of analgesic
      combinations exist, and as such, we have yet to identify the optimal ED pain management
      strategy for children with MSK-T. A larger trial with careful control over principal sources
      of bias and a rigorous approach to safety data collection will provide clinicians with strong
      evidence regarding efficacy and safety on new therapeutic strategies for pain management
      related to MSK-T in the pediatric EDs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2013</start_date>
  <completion_date type="Actual">June 22, 2015</completion_date>
  <primary_completion_date type="Actual">June 22, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity - Percentage of Children Who Achieved VAS &lt; 30 mm</measure>
    <time_frame>60 minutes post-analgesia</time_frame>
    <description>Percentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes.
The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Event - Side Effects and Serious Adverse Events</measure>
    <time_frame>60, 90 and 120 minutes</time_frame>
    <description>To verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Musculoskeletal Injury</condition>
  <arm_group>
    <arm_group_label>oral morphine and oral ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morphine and placebo of ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen and placebo of morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral morphine and oral ibuprofen</intervention_name>
    <description>The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
    <arm_group_label>oral morphine and oral ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral morphine</intervention_name>
    <description>Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
    <arm_group_label>morphine and placebo of ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral ibuprofen</intervention_name>
    <description>oral ibuprofen combine to a placebo is the active comparator</description>
    <arm_group_label>ibuprofen and placebo of morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 6 and 17 years

          -  Presenting to the ED with a musculoskeletal (MSK) trauma to either of the upper or
             lower limbs that is neither obviously deformed, nor neurovascularly compromised

          -  Self-reported pain score &gt;29 mm on a 0 to 100mm Visual Analogue Scale (VAS)

          -  Able to understand French or English.

        Exclusion Criteria:

          -  Known allergy to morphine, ibuprofen, or artificial colouring

          -  MSK trauma that are suspected to be due to child abuse, as determined by the triage
             nurse

          -  Inability to self-report pain

          -  Chronic pain issues that require daily analgesic use

          -  NSAID or opioid analgesic use within three hours prior to presentation to triage
             (Exception of acetaminophen)

          -  Trauma to more than one limb (except fingers and toes)

          -  Known hepatic or renal disease/dysfunction

          -  Known bleeding disorder

          -  Neuro-cognitive disability that precludes patients from assenting and participating to
             the study.

          -  Known history of snoring consistently for the past 5 nights
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Le May, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Justine's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 3C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <results_first_submitted>November 22, 2016</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Sylvie Le May</investigator_full_name>
    <investigator_title>Professor and Researcher</investigator_title>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>analgesia</keyword>
  <keyword>musculoskeletal injury</keyword>
  <keyword>emergency</keyword>
  <keyword>opioids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Assessed for eligibility (n=5127) Excluded (n=4626)
Not meeting inclusion criteria (n=1670)
Excluded as per exclusion criteria (n=663)
Declined to participate (n=874)
Not evaluated (n=1144)
Other reasons (n=275) Randomized (n=501)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Morphine and Oral Ibuprofen</title>
          <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
        </group>
        <group group_id="P2">
          <title>Morphine and Placebo of Ibuprofen</title>
          <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
        </group>
        <group group_id="P3">
          <title>Ibuprofen and Placebo of Morphine</title>
          <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99">Received allocated intervention (n=98)
Did not receive intervention (n=1)</participants>
                <participants group_id="P2" count="201">Received allocated intervention (n=198)
Did not receive allocated intervention (n=3)</participants>
                <participants group_id="P3" count="201">Received allocated intervention (n=199)
Did not receive allocated intervention (n=2)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Available at T-60</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Avalaible at T-90</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Morphine and Oral Ibuprofen</title>
          <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
        </group>
        <group group_id="B2">
          <title>Morphine and Placebo of Ibuprofen</title>
          <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
        </group>
        <group group_id="B3">
          <title>Ibuprofen and Placebo of Morphine</title>
          <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="177"/>
            <count group_id="B4" value="456"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" spread="2.6"/>
                    <measurement group_id="B2" value="11.7" spread="2.7"/>
                    <measurement group_id="B3" value="12.0" spread="2.7"/>
                    <measurement group_id="B4" value="11.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>6-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VAS score at Baseline - Continuous</title>
          <description>The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="15.5"/>
                    <measurement group_id="B2" value="60.8" spread="15.8"/>
                    <measurement group_id="B3" value="61.0" spread="17.1"/>
                    <measurement group_id="B4" value="60.9" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VAS score at Baseline stratified by pain intensity</title>
          <description>The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>30-69 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 69 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury type - n(%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fracture</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Soft tissue injury</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury location - n(%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Wrist</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ankle</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Knee</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Foot</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Elbow</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Forearm</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity - Percentage of Children Who Achieved VAS &lt; 30 mm</title>
        <description>Percentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes.
The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
        <time_frame>60 minutes post-analgesia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Morphine and Oral Ibuprofen</title>
            <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
          </group>
          <group group_id="O2">
            <title>Morphine and Placebo of Ibuprofen</title>
            <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen and Placebo of Morphine</title>
            <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity - Percentage of Children Who Achieved VAS &lt; 30 mm</title>
          <description>Percentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes.
The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="24.2" upper_limit="43.1"/>
                    <measurement group_id="O2" value="29.3" lower_limit="23.2" upper_limit="36.1"/>
                    <measurement group_id="O3" value="29.9" lower_limit="23.7" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Event - Side Effects and Serious Adverse Events</title>
        <description>To verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study</description>
        <time_frame>60, 90 and 120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Morphine and Oral Ibuprofen</title>
            <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
          </group>
          <group group_id="O2">
            <title>Morphine and Placebo of Ibuprofen</title>
            <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen and Placebo of Morphine</title>
            <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Event - Side Effects and Serious Adverse Events</title>
          <description>To verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Side effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Morphine and Oral Ibuprofen</title>
          <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
        </group>
        <group group_id="E2">
          <title>Morphine and Placebo of Ibuprofen</title>
          <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
        </group>
        <group group_id="E3">
          <title>Ibuprofen and Placebo of Morphine</title>
          <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Others</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>High attrition rate between the time of randomization and the 120 minutes following analgesic administration; The dose of oral morphine was within the recommended range, but higher doses have been used in other trials for MSK pain relief in children.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sylvie Le May</name_or_title>
      <organization>CHU Ste-Justine Hospital</organization>
      <phone>514-343-6384</phone>
      <email>sylvie.lemay@umontreal.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

